Black Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) announced that CEO David M. Epstein, Ph.D., will present a business update at the BMO 2020 Healthcare Conference on June 23, 2020, at 2:00 PM ET. The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for three weeks. Black Diamond focuses on precision oncology and aims to develop small molecule, tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers using its proprietary MAP technology platform.
- None.
- None.
CAMBRIDGE, Mass. and NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the BMO 2020 Prescriptions for Success Healthcare Conference. The presentation will take place on Tuesday, June 23, 2020, at 2:00 PM ET.
A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.
About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts:
For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com
For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com
FAQ
When will Black Diamond Therapeutics present at the BMO Healthcare Conference?
Who is presenting for Black Diamond Therapeutics at the conference?
How can I access the presentation by Black Diamond Therapeutics?
Is there a replay available for Black Diamond Therapeutics' presentation?
What is the focus of Black Diamond Therapeutics' work?
